Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of MF59-Adjuvanted Quadrivalent Influenza Vaccine in Adults ≥ 65 Years
NCT02587221Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Sep 2016
- Primary completion
- Jul 2018
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 12
01
Overview
A Phase 3 trial of influenza vaccine (surface antigen, inactivated, adjuvanted) in influenza, sponsored by CSL Seqirus. Started Sep 2016; status: completed.
02
Drugs
influenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02587221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587221.